Urothelial Cancer Drug Pipeline — PatSnap Eureka
Urothelial Cancer Drug Pipeline: Enfortumab Vedotin & FGFR Strategies
Urothelial carcinoma — the fourth most common cancer in men — is driving an accelerating wave of ADC, FGFR inhibitor, and checkpoint combination patents. Explore the IP landscape powering the next generation of bladder cancer therapy.
A High-Priority Oncology Indication With Multiple Validated Targets
Urothelial carcinoma (UC) is described across the retrieved patent dataset as "the fourth most common cancer in men and eleventh most common in women," with the metastatic form carrying a 5-year mortality rate of approximately 85%. This unmet need has driven a concentrated wave of IP activity across several distinct molecular target classes.
Nectin-4 (191P4D12 protein) is the most frequently occurring target in the dataset. Nectin-4 is a cell-surface protein highly expressed in bladder cancer and forms the basis of enfortumab vedotin (EV), an ADC conjugating an anti-Nectin-4 antibody to MMAE. Multiple Agensys, Inc. patents describe Nectin-4 as a validated therapeutic target in both muscle-invasive urothelial cancer (MIUC) and locally advanced/metastatic UC (la/mUC).
FGFR2 and FGFR3 are the highest-specificity molecular biomarkers in FGFR-directed filings. Janssen Pharmaceutica NV's extensive patent portfolio centers on FGFR3 point mutations (S249C, R248C, Y373C, G370C) and fusion genes (FGFR3-TACC3 V1/V3, FGFR3-BAIAP2L1) as companion-diagnostic biomarkers and therapeutic targets for erdafitinib. According to the National Cancer Institute, FGFR alterations are present in a meaningful subset of UC patients, making them actionable targets for precision therapy.
The PD-1/PD-L1 axis is the dominant immunotherapy scaffold across the dataset, with anti-PD-1 agents (pembrolizumab, nivolumab, toripalimab, cetrelimab) and anti-PD-L1 agents (atezolizumab, durvalumab) appearing in combination strategies across virtually every modality cluster. Learn more about PatSnap's life sciences IP intelligence solutions for tracking checkpoint inhibitor patent landscapes.
HER2 (ERBB2) is addressed by RemeGen Co., Ltd. patents disclosing disitamab vedotin (RC48), an anti-HER2 ADC with MMAE payload, for UC including patients with low HER2 IHC expression (1+) — a population not well served by standard HER2-directed therapies. The FDA continues to expand HER2-targeted approvals, making this low-expression signal strategically significant.
IP Activity Signals Across Modalities & Assignees
All data derived from the PatSnap Eureka patent dataset. Relative filing activity reflects patent family count and jurisdictional breadth across the retrieved dataset.
Top Assignees by UC Patent Filing Breadth
Janssen Pharmaceutica NV leads with 15+ patent families across 10+ jurisdictions; Agensys (Astellas) second with multi-jurisdictional Nectin-4 ADC filings spanning 2023–2025.
FGFR3 Mutations Covered by Erdafitinib Patent Claims
Janssen's companion diagnostic strategy enumerates four specific FGFR3 point mutations and three fusion variants as eligibility criteria.
EV Combination Strategy — Patent Coverage Map
Enfortumab vedotin is the anchor agent in multiple combination architectures, from approved dual therapy to emerging triple and dual-ADC approaches.
Seven Drug Modality Clusters Shaping the Urothelial Cancer Pipeline
All modalities below are derived from the retrieved patent dataset. Evidence source is patents only — no academic papers were retrieved for these modalities.
Nectin-4 ADCs — Enfortumab Vedotin & Next-Generation Agents
The most patent-active modality in this dataset. EV targets Nectin-4 via a human IgG1 anti-Nectin-4 monoclonal antibody conjugated to MMAE. Multiple Agensys, Inc. patents describe EV monotherapy in MIBC and MIUC for cisplatin-ineligible patients, including neoadjuvant protocols preceding radical cystectomy and pelvic lymph node dissection (RC+PLND), with a pathologic complete response rate (pCRR) target of ≥30% and pathologic downstaging rate (pDSR) ≥50%. Eli Lilly has also filed a CN patent for a novel Nectin-4 ADC for patients who have relapsed on or are ineligible for EV, explicitly addressing resistance to EV and PD-1/PD-L1 inhibitors and prior platinum chemotherapy.
pCRR target ≥30% · pDSR target ≥50%FGFR Tyrosine Kinase Inhibitors — Erdafitinib & Infigratinib
Janssen Pharmaceutica NV accounts for the largest single-assignee patent cluster in this dataset, with over 15 patent families across WO, US, CA, AU, IL, MX, BR, NZ, SG, and JP jurisdictions, all directed at FGFR inhibitor use in UC. The primary agent is erdafitinib (a pan-FGFR inhibitor), described for use in la/mUC harboring FGFR alterations who have progressed on or after a checkpoint inhibitor. Janssen's filings explicitly describe methods of treating UC "with an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor." A second FGFR inhibitor, infigratinib, appears in patents from QED Therapeutics, Inc. targeting upper tract urothelial carcinoma (UTUC) and non-muscle invasive bladder cancer (NMIBC). Learn more about PatSnap's patent landscape analytics for tracking FGFR inhibitor IP.
Erdafitinib approved · Infigratinib in UTUC/NMIBCADC + Immune Checkpoint Inhibitor Combinations
A major combination theme across the dataset. Three distinct ADC targets appear in combination with PD-1/PD-L1 checkpoint inhibitors. Agensys has filed extensively for EV + pembrolizumab in la/mUC across multiple jurisdictions, covering cisplatin-eligible and cisplatin-ineligible patients. RemeGen Co., Ltd. discloses synergistic combination of disitamab vedotin with PD-1 or PD-L1 antibodies, with reported efficacy even in patients with low HER2 IHC expression (1+) — a potentially expanded patient population. The European Medicines Agency has also been tracking ADC-checkpoint combinations as a regulatory priority.
EV + pembrolizumab · HER2 ADC + IOFGFR Inhibitor + Anti-PD-1 Combinations
Janssen Pharmaceutica NV's most clinically informative filings describe erdafitinib (oral, ~8 mg/day) combined with cetrelimab (anti-PD-1, ~240 mg IV every 2 weeks) in patients harboring at least one FGFR2 or FGFR3 genetic alteration with locally advanced or metastatic UC. The JP patent explicitly states inclusion criteria of "at least one FGFR2 and/or FGFR3 gene alteration," establishing a biomarker-selected clinical trial design. The 2024 WO and 2025 CA Janssen filings describe patients who "progressed on or after 1 or more prior treatments that included a checkpoint inhibitor," establishing a clinically defined second-line or later patient population.
Erdafitinib ~8mg/day · Cetrelimab ~240mg IV Q2WPD-1 Antagonist + Eribulin
Merck Sharp & Dohme Corp. (co-filed with Eisai R&D Management Co., Ltd.) has an extensive multi-jurisdictional patent family for the combination of a PD-1 antagonist with eribulin (a halichondrin-class microtubule inhibitor), citing NCI Protocol No. 7435 as a Phase 1/2 study evaluating eribulin monotherapy in metastatic UC, with demonstrated clinical benefit. This combination spans WO, US, CA, EP, AU, SG, IL, IN, and MX jurisdictions.
NCI Protocol No. 7435 · Phase 1/2 eribulin dataDual ADC Combination — Trop-2 ADC + Nectin-4 ADC
A 2025 WO filing from Gilead Sciences, Inc. is among the most recent and novel filings in this dataset, disclosing dual-ADC combinations involving a Trop-2 ADC (sacituzumab govitecan, sac-TMT, or datopotamab deruxtecan) combined with EV (Nectin-4 ADC), with or without an anti-PD(L)-1 antibody, specifically for UC. This dual-ADC approach targeting two distinct tumor-associated antigens simultaneously represents a potentially novel treatment architecture for post-EV or EV-pretreated UC patients. Track this emerging IP direction on the PatSnap platform.
Gilead 2025 WO · Post-EV architectureIP Strategy Signals & Competitive Implications
Key strategic observations derived from the patent dataset. All claims traceable to retrieved patent filings.
EV + Pembrolizumab — Highest-Density Combination
The volume, geographic breadth, and recency of Agensys filings (2023–2025, covering cisplatin-eligible and ineligible patients, neoadjuvant and la/mUC settings) suggest this combination represents a commercial priority of the first order. IP strategists should assess freedom-to-operate implications for any competing Nectin-4 or anti-PD-1 UC program.
Janssen's FGFR Portfolio — Most Comprehensive in Dataset
Coverage of specific FGFR3 mutation types (S249C, R248C, Y373C, G370C) and fusion variants (FGFR3-TACC3, FGFR3-BAIAP2L1) in combination with anti-PD-1 across 10+ jurisdictions constitutes a deep genomic-to-clinical IP chain. Drug developers targeting FGFR-altered UC should closely evaluate Janssen's sequence in the post-checkpoint-inhibitor second-line setting.
Combination Approaches & Next-Generation Architectures
Eight distinct combination strategies identified across the retrieved patent dataset, spanning approved combinations to early-stage IP directions. Data sourced from PatSnap patent analytics.
| Combination Strategy | Key Assignee(s) | Filing Recency | Patient Population | Development Signal |
|---|---|---|---|---|
| EV + Pembrolizumab (Nectin-4 ADC + anti-PD-1) | Agensys / Astellas | 2023–2025 WO/US/CA/CN | Cisplatin-eligible & ineligible la/mUC | Highest IP density |
| EV + TIGIT antagonist + PD-1 antagonist (triple) | Agensys / Astellas | 2024 WO | la/mUC — early-stage IP direction | Triple combination |
| EV + LAG3 antagonist + PD-1 antagonist (triple) | Agensys / Astellas | 2024 WO | la/mUC — parallel to TIGIT filing | Triple combination |
| Dual ADC: Trop-2 ADC + EV ± anti-PD(L)-1 | Gilead Sciences | 2025 WO | Post-EV or EV-pretreated UC | Most recent filing |
| SIRPα-D1/Fc fusion + EV (myeloid checkpoint) | ALX Oncology | 2023–2024 WO/AU/BR | UC — innate immune modulation | Novel mechanism |
Track every new UC combination filing as it publishes
PatSnap Eureka monitors 120+ patent jurisdictions — set alerts for Nectin-4, FGFR, and checkpoint combination filings in real time. Trusted by 18,000+ innovators worldwide.
What the Patent Rationale Text Reveals About Clinical Progress
While no published clinical trial outcome data (e.g., median PFS, OS, or ORR from completed trials) was retrieved in this dataset, patent rationale text and referenced protocols provide meaningful clinical signals.
NCI Protocol No. 7435 (Phase 1/2, eribulin monotherapy in metastatic UC) is cited in multiple Merck/Eisai patents as foundational clinical evidence for eribulin activity in mUC, providing the Phase 1/2 data rationale for combining eribulin with a PD-1 antagonist.
Erdafitinib post-checkpoint inhibitor sequencing: The 2024 WO and 2025 CA Janssen filings describe patients who "progressed on or after 1 or more prior treatments that included a checkpoint inhibitor," establishing a clinically defined second-line or later patient population. This post-IO sequencing rationale is a consistent theme across FGFR inhibitor filings.
Atezolizumab + ctDNA-guided therapy: Genentech's MX, CA, JP, BR, and WO filings describe ctDNA presence/level as the basis for selecting neoadjuvant or adjuvant atezolizumab, signaling a biomarker-stratified clinical trial design. The ClinicalTrials.gov registry lists multiple ongoing atezolizumab trials in UC. For deeper biomarker IP tracking, explore PatSnap's life sciences solutions.
Toripalimab + TMB ≥10 mutations/Mbp: Shanghai Junshi Biosciences' WO and CN filings establish TMB ≥10 mutations/Mbp and SMARCA4/RB1 mutations as companion diagnostic criteria, suggesting a biomarker-selected clinical trial design. WHO cancer data underscores the global burden driving these precision approaches.
Access the full companion diagnostic and biomarker IP landscape via PatSnap's open data API for integration into your R&D workflows.
Urothelial Cancer Drug Pipeline — key questions answered
Enfortumab vedotin (EV) targets Nectin-4 via a human IgG1 anti-Nectin-4 monoclonal antibody conjugated to MMAE, a microtubule-disrupting cytotoxic payload. MMAE disrupts tubulin polymerization following ADC internalization via Nectin-4-mediated endocytosis. Nectin-4 is a cell-surface protein highly expressed in bladder cancer.
Janssen's patents enumerate specific FGFR3 mutations (S249C, R248C, Y373C, G370C) and fusion variants (FGFR3-TACC3 V1, FGFR3-TACC3 V3, FGFR3-BAIAP2L1) as companion diagnostic criteria for erdafitinib eligibility. FGFR2 alterations are also included in combination filings.
Agensys filings across 2023–2025 in WO, US, CA, and CN cover both cisplatin-eligible and cisplatin-ineligible la/mUC patients, encompassing first-line and subsequent-line settings. The EV + pembrolizumab combination is the most patent-dense combination in the dataset, suggesting it represents a commercial priority of the first order.
Biomarker-guided immunotherapy selection includes TMB ≥10 mutations/Mbp and SMARCA4/RB1 mutations for toripalimab response (Shanghai Junshi Biosciences), ctDNA presence/level for atezolizumab selection (Genentech), FGFR2/3 genotype for erdafitinib eligibility (Janssen), and PD-L1 IHC across multiple modalities.
Disitamab vedotin (RC48) is an anti-HER2 ADC with MMAE payload developed by RemeGen Co., Ltd. for UC including patients with low HER2 IHC expression (1+), a population not well served by standard HER2-directed therapies. RemeGen patents highlight clinical signal in patients with low HER2 expression — a population potentially not captured by standard HER2 eligibility thresholds.
Gilead's 2025 WO filing discloses dual-ADC combinations involving a Trop-2 ADC combined with EV (Nectin-4 ADC), with or without an anti-PD(L)-1 antibody. Agensys' 2024 WO filings disclose triple combinations: anti-Nectin-4 ADC + TIGIT antagonist + PD-1 antagonist, and anti-Nectin-4 ADC + LAG3 antagonist + PD-1 antagonist. ALX Oncology discloses a SIRPα-D1 domain variant/Fc fusion polypeptide combined with EV.
Still have questions about the urothelial cancer patent landscape? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka About UC PatentsAccelerate Your Urothelial Cancer Drug Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track ADC pipelines, FGFR inhibitor IP, and checkpoint combination strategies across 120+ jurisdictions.
References
- FGFR tyrosine kinase inhibitors and Anti-PD1 agents for the treatment of urothelial carcinoma — Janssen Pharmaceutica NV, 2021, WO [Patent]
- Cancer treatment (erdafitinib in FGFR-altered mUC post-checkpoint inhibitor) — Janssen Pharmaceutica NV, 2025, CA [Patent]
- Treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib — Janssen Pharmaceutica NV, 2024, WO [Patent]
- Treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib — Janssen Pharmaceutica NV, 2026, AU [Patent]
- FGFR tyrosine kinase inhibitors and anti-PD1 agents for treating urothelial carcinoma — Janssen Pharmaceutica N.V., 2023, JP [Patent]
- FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma — Janssen Pharmaceutica NV, 2022, US [Patent]
- FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma — Janssen Pharmaceutica NV, 2021, SG [Patent]
- FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma — Janssen Pharmaceutica NV, 2020, CA [Patent]
- Methods of treating urinary system cancers — QED Therapeutics, Inc., 2022, IL [Patent]
- Treating locally advanced or metastatic urothelial cancer with Anti-191p4d12 antibody drug conjugates in combination with pembrolizumab — Agensys, Inc., 2025, WO [Patent]
- Methods for treating patients with locally advanced or metastatic urothelial cancer with ADC that bind 191p4d12 proteins in combination with pembrolizumab — Agensys, Inc., 2025, CA [Patent]
- Methods for treating muscle invasive urothelial cancer or muscle invasive bladder cancer with ADC that bind to 191p4d12 proteins — Agensys, Inc., 2025, US [Patent]
- Nectin-4 Antibodies and Antibody-Drug Conjugates — Eli Lilly and Company, 2026, CN [Patent]
- Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancer — RemeGen Co., Ltd., 2022, WO [Patent]
- Combination of a PD-1 antagonist and eribulin for treating urothelial cancer — Merck Sharp & Dohme Corp., 2018, WO [Patent]
- Combination of a PD-1 antagonist and eribulin for treating urothelial cancer — Merck Sharp & Dohme Corp., 2019, US [Patent]
- Combination therapies for treating cancers (Dual ADC: Trop-2 + Nectin-4) — Gilead Sciences, Inc., 2025, WO [Patent]
- Combination therapies for treating urothelial carcinoma (SIRPα + EV) — ALX Oncology Inc., 2023, WO [Patent]
- National Cancer Institute — Bladder Cancer Treatment
- U.S. Food and Drug Administration — HER2-Targeted Therapy Approvals
- European Medicines Agency — ADC and Checkpoint Combination Regulatory Guidance
- ClinicalTrials.gov — Urothelial Carcinoma Trials Registry
- World Health Organization — Global Cancer Data
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.